Spelling suggestions: "subject:"retinoblastoma."" "subject:"retinoblastomas.""
91 |
Gene Expression Profiling And Insights Into The Involvement Of The Insulin Signaling Pathway In Oral CancerChakraborty, Sanjukta 03 1900 (has links)
1. Despite extensive research on oral squamous cell carcinoma (OSCC), its five-year survival rate has not improved for the last two decades. Effective treatment of OSCC requires the identification of molecular targets to design appropriate therapeutic strategies. To this end, DDRT-PCR analysis was used to identify molecular markers, which could be used as
therapeutic targets.
2. DDRT-PCR in combination with reverse Northern analysis identified 25 differentially expressed genes in oral tumors. Fourteen genes did not show homology to any known gene in the database and therefore may represent non-specific genomic DNA sequences or novel genes that have not yet been identified. The remaining 11 genes showed homology to known genes such as DIAPH1, NJMU-R1, RBM28, PCNA, GLTP, MTATP6, ZKSCAN1, TNKS2, PAM, TUBB2C and C14orf154. TNKS2, PAM, TUBB2C and C14orf154 showed downregulation and the remaining seven genes were upregulated in oral tumor samples.
3. To reconfirm the results of DDRT-PCR and reverse Northern blot analyses, Northern blot analysis was carried out on matched normal and tumor samples for a few genes. As expected, PCNA, NJMU-R1 and ZKSCAN1 showed upregulation, whereas TUBB2C showed
downregulation in the tumor sample. PCNA was also found to be upregulated in tumor
samples at the protein level.
4. The expression of eight differentially expressed genes (viz., DIAPH1, NJMU-R1, RBM28, PCNA, GLTP, TNKS2, PAM and TUBB2C) was also validated in a panel of 16 matched
normal and tumor samples. The mean mRNA expression levels of GLTP, PCNA, RBM28,
NJMU-R1 and DIAPH1 were significantly greater in tumor samples than in normal samples. The mean expression levels of TNKS2, PAM and TUBB2C were significantly lower in tumor samples than in normal samples.
5. As some of the genes like NJMU-R1, RBM28, GLTP and PAM are found to differentially
regulated in a majority of the tumors, they could be used as potential markers in oral cancer.
6. Tuberin and hamartin have been placed as a complex in the insulin signaling pathway and are known to negatively regulate this pathway. Since overexpression of TSC2 has been previously shown to exert antitumor effect on two oral cancer cell lines, and some components of the insulin signaling pathway have already been implicated in head and neck cancers, we reasoned that both TSC genes and other key players of this pathway might be differentially regulated in oral tumors. Northern blot analysis showed downregulation of the TSC2 gene in an oral tumor sample. In order to further validate the expression pattern of the TSC2 gene, a semiquantative RT-PCR analysis was carried out in a panel of 16 matched normal and tumor samples. The mean expression level of TSC2 was significantly lower in tumor samples than in normal tissue samples. The mean expression level of its interacting
partner TSC1 was also significantly lower in tumor samples than in normal tissue samples,
suggesting the involvement of these genes in the etiology of oral cancer. TSC1 and TSC2
were also downregulated in eight matched normal and tumor samples at the protein level. We wanted further to determine the expression of both TSC genes in cell lines. Interestingly, TSC2 did not show a detectable level of expression in an oral cancer cell line SCC 131, whereas it was expressed in two other oral cancer cell lines KB and SCC 104 as well as in
four non-oral cell lines: A549, HEK-293T, HeLa and HepG2 at the protein level. The TSC2 expression in KB was, however, lower than in other cell lines. TSC1 was expressed in all the cell lines, albeit at different levels. The TSC1 expression was lower in SCC 131 as compared to two other cell lines KB and SCC 104.
7. Given the fact that both are tumor suppressors, it was hypothesized that LOH, inactivating somatic mutations and/or promoter methylation might be playing a role for their downregulation in oral tumors. Mutation analysis of all the coding regions of both the TSC genes failed to detect any mutation in a panel of 25 tumor samples. However, seven normal population variants were identified in different patients. Our analysis of the matched peripheral blood and tumor DNA samples from 52 patients showed LOH at both the TSC loci. At the TSC1 locus, 17/48 (35.42%) tumors showed an allelic loss for one or more markers. At the TSC2 locus, LOH was found in 18/48 (37.5%) informative cases. Nine patients (9/48, 18.75%) had LOH at both the TSC loci. Since PTEN is another tumor suppressor in the insulin signaling pathway, we then sought to determine if LOH is also present in the PTEN candidate region in a panel of 50 matched samples. Microsatellite analysis using three markers showed a low LOH rate of 13% in tumor samples.
8. As the OSCC cell line SCC 131 did not show a detectable level of TSC2 expression, we treated this cell line with methylation inhibition drug 5-azacytidine. The treatment restored the expression of TSC2 and increased the expression of TSC1, suggesting that the promoter methylation and LOH are the important mechanisms for their downregulation. In order to see if the downregulation of the TSC genes is due to their promoters being methylated in tumors
from the patients, we examined the methylation status of their promoters in 16 oral tumors, three normal oral tissues, two peripheral blood DNA samples from normal individuals and two cell lines HeLa and SCC 131 by COBRA. Our repeated efforts to amplify the TSC1 promoter using different DNA polymerases failed. However, we were able to successfully amplify the 571 bp long TSC2 promoter. Our analysis showed methylation of the TSC2 promoter in all tumors and two cell lines. As expected, the TSC2 promoter was not methylated in normal oral tissues and control blood DNA samples. Our bisulfite sequencing data suggested a low level and a considerable heterogeneity of methylation.
9. Using Fisher’s exact test, no correlation was found between LOH at the TSC loci and
different clinical parameters such as age, sex, T classification, stage, grade, histology, tobacco habits and lymph node metastasis.
10. Using Fisher’s exact test, no correlation was found between the TSC2 promoter methylation and its downregulation in 16 tumor samples. We believe that this could be due to small sample size.
11. Since TSC1 and TSC2 are important regulators of the insulin pathway, it was
hypothesized that other key players of this pathway might also be dysregulated in oral
cancer. To this end, the expression pattern of some of the major regulators of the insulin pathway (viz., PI3K, AKT, PDK1, RHEB, mTOR, S6K1, S6, eIF4E, 4E-BP1, PTEN, 14-3-3゚ and IRS1) was investigated using semiquantative RT-PCR in a panel of 16 matched normal and tumor samples. The mean expression levels of the following genes showed significant upregulation in tumor samples: AKT, PI3K, PDK1, RHEB, mTOR, S6K1, S6 and eIF4E. On the other hand, 4E-BP1 and PTEN showed significant downregulation in tumor tissues. No significant difference in the expression was found for 14-3-3゚ and IRS1 between tumor and normal tissues. The expression pattern of some of these genes was also analyzed at the protein level using Western blot analysis and eight matched normal and tumor tissues. The level of total AKT was upregulated in 2/8 tumor samples only. However, phosphorylated-AKT (Thr308) showed upregulation in 6/8 samples. p70S6K1 and phosphorylated-p70S6K1 (Thr389) were upregulated in 8/8 and 6/8 tumor samples, respectively. Increase in the phosphorylated forms of both AKT and its downstream effector p70S6K1 suggested an increase in their kinase activity, indicating a constitutive activation of this pathway in oral cancer.
12. Based on our findings of mutation analysis, LOH study, 5-azacytidine treatment of an oral cancer cell line and COBRA analysis, we suggest that LOH at the TSC gene loci and promoter methylation are important mechanisms for the downregulation of the TSC genes. Loss of function of these genes may thus contribute to the constitutive activation of the insulin signaling pathway in oral cancer, leading to overall cell growth and proliferation. Our
studies have shown that several key members of this pathway show aberrant expression in a subset of cancers of the oral cavity and can provide useful therapeutic targets. Several inhibitors of the insulin signaling pathway, such as rapamycin and its derivatives which inhibit mTOR and the PI3K inhibitor wortmannin, are now being actively evaluated for clinical trials for other cancers. We suggest that these inhibitors could also be evaluated for the treatment of oral cancer in future. Our differential display analysis has served to identify
several genes that may be important for the onset and progression of oral cancer. Further analysis of these genes is warranted.
|
92 |
Lack of Point Mutations in Exons 11–23 of the Retinoblastoma Susceptibility Gene RB-1 in Liver Metastases of Colorectal CarcinomaHildebrandt, Bert, Heide, I., Thiede, Christian, Nagel, S., Dieing, Annette, Jonas, S., Neuhaus, Peter, Rochlitz, Christoph, Riess, Hanno, Neubauer, Andreas 12 February 2014 (has links) (PDF)
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
|
93 |
Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast CancerRobinson, Tyler 18 June 2014 (has links)
Triple negative breast cancer (TNBC) represents an aggressive subtype for which only chemotherapy is available. The RB1 tumour suppressor is frequently lost in human breast cancer, primarily in TNBC. Loss of RB1 deregulates the cell cycle and is thought to affect BC response to endocrine, radiation, and chemotherapy. However, the global chemosensitivity of Rb null BC is not known. Here I demonstrate that RB1-deficient TNBC cells are highly sensitive to radiation, and moderately sensitive to doxorubicin and methotrexate. However, loss of RB1 does not increase sensitivity to multiple other drugs. Moreover, a non-biased screen of 2 RB-deficient versus 2 RB-proficient lines with ~3500 drugs did not reveal any difference in sensitivity, but identified disulfiram as a potent drug, which compared favourably with current chemotherapeutics against TNBC. Disulfiram’s efficacy was validated against 13 human TNBC
lines with an average IC50 of 300nM. IQGAP1 was identified as a potential target of disulfiram.
|
94 |
Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast CancerRobinson, Tyler 18 June 2014 (has links)
Triple negative breast cancer (TNBC) represents an aggressive subtype for which only chemotherapy is available. The RB1 tumour suppressor is frequently lost in human breast cancer, primarily in TNBC. Loss of RB1 deregulates the cell cycle and is thought to affect BC response to endocrine, radiation, and chemotherapy. However, the global chemosensitivity of Rb null BC is not known. Here I demonstrate that RB1-deficient TNBC cells are highly sensitive to radiation, and moderately sensitive to doxorubicin and methotrexate. However, loss of RB1 does not increase sensitivity to multiple other drugs. Moreover, a non-biased screen of 2 RB-deficient versus 2 RB-proficient lines with ~3500 drugs did not reveal any difference in sensitivity, but identified disulfiram as a potent drug, which compared favourably with current chemotherapeutics against TNBC. Disulfiram’s efficacy was validated against 13 human TNBC
lines with an average IC50 of 300nM. IQGAP1 was identified as a potential target of disulfiram.
|
95 |
Pathways Linking Deregulated Proliferation to Apoptosis: a DissertationRogoff, Harry A. 29 April 2004 (has links)
Proper regulation of cellular proliferation is critical for normal development and cancer prevention. Most, if not all, cancers contain mutations in the Rb/E2F pathway, which controls cellular proliferation. Inactivation of the retinoblastoma protein (Rb) can occur through Rb loss, mutation, or inactivation by cellular or viral oncoproteins leading to unrestrained proliferation. This occurs primarily by de-repression and activation of the E2F transcription factors, which promote the transition of cells from the G1to S phase of the cell cycle. In order to protect against loss of growth control, the p53 tumor suppressor is able to induce programmed cell death, or apoptosis, in response to loss of proper Rb cell cycle regulation.
E2F1 serves as the primary link between the Rb growth control pathway and the p53 apoptosis pathway. While the pathway(s) linking E2F1 to p53 activation and apoptosis are unclear, it has been proposed that E2F1 activates p53-dependent apoptosis by transactivation of p19ARF leading to inhibition of Mdm2-promoted degradation of p53. We tested this hypothesis, and found that p19ARFis not required for E2F1-induced apoptosis. Instead, we find that expression of E2F1 leads to covalent modifications of p53 that correlate with p53 activation and are required for apoptosis.
The observation that E2F1 induces covalent modification of p53 is consistent with the p53 modifications observed following DNA damage. We therefore hypothesized that E2F1 may be activating components of the DNA damage response to activate p53 and kill cells. Consistent with the DNA damage response, we find that E2F1-induced apoptosis is compromised in cells from patients with the related disorders ataxia telangiectasia and Nijmegen breakage syndrome, lacking functional Atm and Nbs1 gene products, respectively. E2F1-induced apoptosis and p53 modification also requires the human checkpoint kinase Chk2, another component of the DNA damage response. We find that the commitment step in E2F1-induced apoptosis is the induction of Chk2.
Having found that E2F1 requires DNA damage kinases to induce apoptosis, we next examined events upstream of kinase activation. To this end, we observe relocalization of the DNA damage repair MRN complex (composed of Mre11, Nbs1, and Rad50) to nuclear foci specifically following expression of E2F1. Expression of E2F1 also induces relocalization of the DNA damage recognition proteins γH2AX and 53BP1 to nuclear foci, consistent with the location of these complexes observed following DNA double strand breaks. As a consequence of activating some or all of these DNA damage signaling proteins, expression of E2F1 blocks cell cycle progression in diploid human fibroblasts. The observed block in cell cycle progression is found to be, in part, due to activation of a p21-dependent cell cycle checkpoint.
The E7 protein from the oncogenic human papillomavirus (HPV) is able to bind to and inactivate members of the Rb family. HPV infects quiescent, non-cycling cells that lack expression of DNA replication machinery that is essential for replication of the viral genome. By expression of the E7 protein, HPV is able to bypass normal Rb-mediated growth control and induce quiescent cells to enter S phase where the host cell DNA replication enzymes are present for viral replication. We find that expression of E7 can also result in apoptosis that is dependent specifically on E2F1. Additionally, E7-induced apoptosis, like E2F1-induced apoptosis, requires Atm, Nbs1, and Chk2. Expression of E7, like that of E2F1, induces E2F1-dependent covalent modification of p53 that correlates with apoptosis induction.
These findings demonstrate that deregulation of the Rb/E2F growth control pathway leads to activation of an apoptosis program with some similarity to the pathways activated by DNA damage. Our observations suggest that E2F1 not only functions as a sensor for deregulation of Rb, but may also play an important role in regulating cellular growth control in response to other oncogenic stimuli.
|
96 |
In-Depth Characterization of Human Retinoblastoma Subtype 2 and Preclinical Models / Caractérisation approfondie du rétinoblastome humain de sous-type 2 et des modèles précliniquesOttaviani, Daniela 25 January 2019 (has links)
Le rétinoblastome, un cancer pédiatrique de la rétine en développement, est la tumeur intraoculaire la plus fréquente chez l’enfant et représente environ 4 % de tous les cancers infantiles. Bien qu'il s'agisse d'une maladie rare, l'hôpital Curie (centre de référence pour le rétinoblastome en France) accueille environ 50 à 60 nouveaux patients chaque année. Notre groupe a précédemment caractérisé deux sous-types de rétinoblastomes. Les tumeurs de type « cone-like » ou sous-type 1 sont plutôt différenciées et homogènes, présentent une surexpression des gènes liés aux cellules cônes (photorécepteurs) de la rétine, sont diagnostiquées cliniquement plus tôt et regroupent la majorité des formes héréditaires et bilatérales. Les tumeurs « mixed-type » ou sous-type 2, présentent une hétérogénéité intra-tumorale et une surexpression des gènes liés aux cellules des cônes et des cellules ganglionnaires de la rétine, sont enrichies en patients unilatéraux qui sont diagnostiqués cliniquement à des âges plus avancés. Nous avons caractérisé le paysage moléculaire et génomique de 102 rétinoblastomes provenant de trois institutions : l'Institut Curie (France), l'Hôpital Garrahan (Argentine) et l'Hôpital Sant Joan de Déu (Espagne). Le développement d'une signature de méthylation par pyroséquençage pour la classification des échantillons nous a permis d'élargir nos échantillons classés, d'une première série de 72 à notre dernière série de 102 tumeurs. L'analyse du paysage mutationnel de notre série a révélé que les tumeurs du sous-type 2 avaient plus de mutations somatiques par échantillon que les tumeurs du sous-type 1. De plus les gènes BCOR et ARID1A étaient les deux seuls gènes mutés de manière récurrente, et identifiés uniquement dans le sous-type 2. En divisant notre cohorte de tumeurs en sous-type 1 et 2, la distribution des mutations le long de RB1 était significativement différente. Par ailleurs, nous avons identifié une région de la protéine RB1 (dans le Domaine A) enrichie en mutations provenant des tumeurs du sous-type 2, avec très peu de mutations du sous-type 1. En plus, nous avons caractérisé deux événements récurrents de fusion chromosomique perturbant le gène DACH1. Les tumeurs de sous-type 2 sont caractérisées par une surexpression de TFF1, non exprimée dans la rétine normale. L'analyse par immunohistochimie de TFF1 dans des tumeurs localement invasives provenant de l'hôpital Garrahan a révélé la présence de cellules TFF1+ envahissant la région rétrolaminaire du nerf optique. Nous avons exploré un possible rôle oncogène de TFF1 dans le rétinoblastome lié à la survie cellulaire, à la migration cellulaire et à l'invasion cellulaire, qui n'a finalement pas été mis en évidence in vitro. Le sous-type moléculaire 2 regroupe les tumeurs MYCN amplifiées et les tumeurs avec une activation de la voie de signalisation MYC et des gènes cibles de MYC. L'utilisation de JQ1 et OTX015 (inhibiteurs des protéines BET) a fortement réduit la viabilité in vitro de lignées cellulaires de rétinoblastomes représentatives du sous-type 2, avec une régulation négative significative du gène et de la protéine MYC/MYCN. Nos résultats préliminaires suggèrent une nouvelle piste thérapeutique par l'inhibition des protéines BET dans le rétinoblastome. Les modèles précliniques largement utilisés dans la recherche sur le rétinoblastome n'ont pas été caractérisés ou classés au niveau moléculaire. Nous avons utilisé la même approche que pour la classification des tumeurs primaires et avons constaté que la plupart des modèles cellulaires et PDX étudiés étaient classés dans le sous-type moléculaire 2 et partageaient des caractéristiques moléculaires, génomiques et protéiques trouvés dans les tumeurs primaires de ce sous-type moléculaire. En conclusion, nous avons pu caractériser de façon plus approfondie le sous-type 2 des rétinoblastomes, qui semble présenter un phénotype plus agressif et qui est le sous-type représenté dans les modèles précliniques analysés. / Retinoblastoma (RB) is a rare pediatric cancer of the developing retina that represents the most common intraocular tumor in children, and accounts for about 4% of all childhood cancers. Although being a rare disease, the Curie Hospital (the referral center for retinoblastoma in France) treats about 50-60 new patients each year. Our group has previously characterized two retinoblastoma subtypes. The cone-like or subtype 1 tumors rather differentiated and homogenous, presenting an overexpression of genes related to cone photoreceptor retinal cells, clinically diagnosed earlier and grouping the majority of hereditary and bilateral forms. The mixed-type or subtype 2 tumors, displaying an intra-tumoral heterogeneity and showing overexpression of genes related to cone and retinal ganglion cells, are enriched in unilateral patients clinically diagnosed at older ages. The general goal of my thesis was to extend the molecular characterization of these subtype 2 retinoblastomas. We characterized the molecular and genomic landscape of retinoblastoma in a series of 102 primary tumors, integrating samples from three institutions: the Curie Institute (France), the Garrahan Hospital (Argentina) and Sant Joan de Déu Hospital (Spain). The development of a pyrosequencing-based tool for sample classification allowed us to enlarge our classed samples, from an initial series of 72, to our final series of 102 tumors. Analysis of the mutational landscape in our series revealed that tumors from the subtype 2 had significantly more somatic mutations per sample than tumors from the subtype 1. Besides RB1 gene, BCOR and ARID1A where the only two recurrently mutated genes, and identified only in the subtype 2. Distribution of mutations alongside the RB1 gene has so far been analyzed in terms of a single group of retinoblastomas. When splitting our cohort in subtype 1 and subtype 2 tumors, the distribution of mutations was significantly different. Besides, we identified a region of the RB1 protein (in Domain A) enriched in mutations from tumors of the subtype 2, and devoid of mutations of the subtype 1. Besides somatic mutations, we characterized two recurrent chromosomal fusion events disrupting DACH1. Subtype 2 tumors are characterized by an overexpression of TFF1, not expressed in the normal retina. Immunohistochemical analysis of TFF1 in locally invasive tumors coming from the Garrahan Hospital revealed the presence of TFF1+ cells invading the retrolaminar region of the optic nerve. We then explored a possible oncogenic role of TFF1 in retinoblastoma related to cell survival, cell migration and cell invasion, which was not fully uncovered. Molecular subtype 2 regroups the MYCN amplified tumors and tumors with MYC signaling pathway activation and upregulation of hallmark MYC target genes. The use of JQ1 and OTX015 (BET bromodomains inhibitors) strongly reduced the viability in vitro of retinoblastoma cell lines representatives of the subtype 2, together with a significant MYC/MYCN gene and protein downregulation. We provided preliminary results to explore a new therapeutic avenue of BET protein inhibition in retinoblastoma. Preclinical models widely used in retinoblastoma research has not been characterized or classified at the molecular level. We have used the same approach as for primary human tumor’s classification, and found that most cellular and PDX models studied classed in the molecular subtype 2 and shared many of the molecular, genomic and protein characteristics found in primary tumors of this molecular subtype. Taken together, we have performed a deeper characterization of subtype 2 retinoblastomas, which seems to represent a more aggressive phenotype, and is the represented subtype in the preclinical models analyzed.
|
97 |
Efficient Photodynamic Therapy on Human Retinoblastoma Cell LinesWalther, Jan 30 April 2015 (has links)
Die Photodynamische Therapie (PDT) hat sich zunehmend als vielversprechende Methode zur Behandlung von verschiedenen malignen Neubildungen gezeigt. Die photodynamische Zerstörung der Tumore wird erreicht indem zunächst ein Photosensibilisator entweder lokal oder systemisch appliziert wird und im Anschluss an eine gewisse Inkubationszeit die Tumormasse mittels einer Lichtquelle mit einer spezifischen Wellenlänge durchleuchtet wird. Aufgrund der bevorzugten Anreicherung des Photosensibilisators in Tumorzellen, erlaubt diese Methode eine selektive Abtötung des malignen Tumors, während das umliegende Gewebe weitestgehend verschont wird. Diese Eigenschaften und Anforderungen machen die PDT, insbesondere in den Fällen, wo die chirurgische Enukleation als kurative Option erwogen wird, zu einer attraktiven Therapieoption in der Behandlung von Retinoblastomen (Rb). Die extreme Methode der Enukleation wird noch immer angewendet, wenn die Tumoren nicht ausreichend chemosensibel sind, oder wenn sich die Erkrankung aufgrund von unzureichendem Zugang zu medizinischer Versorgung bereits in einem fortgeschrittenen Stadium befindet. In dieser Studie haben wir zunächst In-Vitro-Untersuchungen mit dem neuen kationischen wasserlöslichen Photosensibilisator Tetrahydroporphyrin-Tetratosylat (THPTS) bezüglich seiner photodynamischen Wirkung auf WERI Rb-1 und Y79-Retinoblastomzellen durchgeführt. Dabei konnten wir zeigen, dass weder die Inkubation mit THPTS ohne anschließende Beleuchtung, noch die alleinige Beleuchtung zu einem signifikanten Effekt auf die Proliferation der Rb-Zellen führte. Die Kombination von THPTS mit anschließender Beleuchtung hingegen führte zu einem maximal zytotoxischen Effekt in den Tumorzellen. Darüber hinaus war die Phototoxizität in normalen Primärzellen des Pigmentepithels der Retina geringer, wodurch ein erhöhter phototoxischer Effekt von THPTS in Krebszellen gegenüber diesem normalen Zelltyp der Retina gezeigt werden konnte. Die vorliegenden Ergebnisse bilden eine ermutigende Grundlage für weiterführende in-vivo-Untersuchungen zum therapeutischen Potential dieses vielversprechenden Photosensibilisators mit der Aussicht auf eine potentiell kurative Therapie des Retinoblastoms unter Erhalt von Augapfel und Visus.:Inhaltsverzeichnis
Einleitung 1
Hintergrund und Bedeutung 1
Pathophysiologie 2
Diagnostik und Symptome 3
Klassifizierung 4
Therapie und Prognose 5
Enukleation 5
Perkutane Radiotherapie 6
Brachytherapie 6
Intravenöse Chemotherapie 6
Intraarterielle Chemotherapie 6
Laser-gestützte Verfahren 7
Photodynamische Therapie 7
Mechanismus 7
Eigenschaften von Photosensibilisatoren 8
THPTS-PDT 9
Fragestellung 9
THPTS-PDT on Human Retinoblastoma Cell Lines 11
Zusammenfassung 24
Einleitung 24
Methode 25
Zellkultur primärer humaner Pigmentepithelzellen der Retina (RPE) 25
Photodynamische Therapie von Retinoblastomzellen und RPE-Zellen 25
Clearance von THPTS 25
Real-Time RT-PCR 25
Immunzytochemie und Live-Videoaufnahmen 26
Ergebnisse 26
Effekt der THPTS-PDT auf Retinoblastom-Zelllinien 26
Effekt in Abhängigkeit von Dosis und Einwirkzeit 26
Wirkung der THPTS-PDT auf nicht-maligne Netzhautzellen im Vergleich zu Rb-Zellen 27
Verstoffwechselung von THPTS 27
Genexpression 27
Immunzytochemie und Live-Videoaufnahmen 28
Subzelluläre Anreicherung von THPTS 28
Diskussion 28
ii
Literaturverzeichnis vi
Anhang x
Erklärung über die eigenständige Abfassung der Arbeit x
Wissenschaftliche Publikationen xi
|
98 |
Photosensibilisateurs pour la thérapie photodynamique (PDT) des cancers : impact des modifications structurales sur leur interaction avec des membranes / Photosensitizers for photodynamic therapy (PDT) of cancers : impact of structural changes on their interaction with membranesEssaid, Donia 04 March 2016 (has links)
La photothérapie dynamique (PDT) consiste à injecter un photosensibilisateur (PSr) au patient, puis à illuminer sa tumeur. En présence d’oxygène, le PSr activé entraîne la formation d’oxygène singulet cytotoxique. Nos collaborateurs à l’Institut Curie ont synthétisé des dérivés porphyriniques glycoconjugués(TPP) pour traiter le rétinoblastome par PDT.Des études de caractérisation de ces TPP in vitro ont montré une internalisation dans la cellule par voie passive. C’est dans ce contexte que nous avons analysé l’interaction de certaines TPP avec les lipides membranaires.Dans un premier temps, cette interaction a été étudiée par une approche chromatographique sur des colonnes C18/C8, PolarTec, HILIC et IAM. Nous avons démontré une variation de l’interaction selon la structure des TPP. Par la suite, nous avons mis en évidence par DSC, les changements d’organisation de bicouches phospholipidiques produits par deux TPP d’intérêt, et déterminé par FTIR-ATR, la localisation de la perturbation au niveau des têtespolaires ou des chaines aliphatiques des lipides.Cette approche a été poursuivie par l’évaluation de la localisation des TPP à l’échelle cellulaire,par microspectroscopie IR couplée au rayonnement synchrotron. Une discrimination des TPP a été mise en évidence par des outils chimiométriques pour les cellules Y79, mais pas pour les lignées WERI-Rb1 ni ARPE-19. Afin de développer un modèle membranaire artificielde rétinoblastome, nous avons réalisé par spectrométrie de masse (Orbitrap) une analyse lipidomique approfondie des phospholipides des membranes plasmiques et mitochondriales des lignées Y79 et ARPE-19,. Nous avons analysé les propriétés visco-élastiques des extraits membranaires et proposé un modèle artificiel complexe mimant au moins partiellement ces propriétés. Ce modèle pourrait permettre le criblage in vitro des TPP. / Photodynamic therapy (PDT) is atreatment modality in which a photosensitizer(PSr) is injected to a patient. Then the tumor isilluminated with a laser. The excited PSrinduces the production of cytoxic singletoxygen. Our collaborators at the Institut Curiehave synthesized glycoconjugated tetraphenylporphyrins(TPP) for the treatment ofretinoblastoma by PDT. These compoundswere characterized in vitro and studies showedthat the most promising porphyrin crossed thecell membrane by passive transport. It is in thiscontext that this research was developed: theobjective was to study the interaction of aseries of porphyrins with membrane lipids.Firstly, porphyrin interaction with lipids wasstudied by a chromatographic approach onC18/C8, PolarTec, HILIC and IAM columns.Results showed a variation in the interactionaccording to porphyrin structures.Then, we demonstrated the effect of two TPPson phospholipid bilayers organization by DSC,and determined the localization of thisinteraction (polar heads or lipid aliphaticchains) by FTIR-ATR. The effect of TPPs onlipids and proteins was studied at the cellularlevel by IR microspectroscopy coupled withsynchrotron radiation. A discrimination ofporphyrins could be made by chemometrictools for Y79 cells but not for WERI-Rb1 norARPE-19 ones. In order to develop an artificialmembrane model, we performed lipidomicanalysis by mass spectrometry (Orbitrap) ofplasma and mitochondrial lipid membranes ofY79 and ARPE-19 cells. We determined theviscoelastic properties of lipid extracts andproposed an artificial lipid model partiallymimicking these viscoelastic properties. Thismodel could allow TPP screening in vitro.
|
99 |
Expressão imuno-histoquímica das proteínas p16, ciclina D1, CDK4, pRb, p53 e p21 em melanomas cutâneos de cabeça, pescoço e tronco e sua relação com prognóstico / Prognostic impact of p16, cyclin D1, CDK4, pRb, p53 and p21 expression in head, neck and trunk melanomasSantos, André Bandiera de Oliveira 11 May 2010 (has links)
O melanoma cutâneo é a neoplasia de pele de maior mortalidade. A imprevisibilidade de sua evolução é uma de suas características principais, o tratamento do tumor primário é, atualmente, de pouca morbidade e, na doença disseminada, as opções terapêuticas são pouco eficazes. É fundamental a pesquisa de marcadores tumorais que permitam a previsão da evolução, melhor compreensão da patogênese do melanoma e possibilitem a descoberta de alvos moleculares. Nesse contexto, estudos genéticos mostraram a importância da regulação do ciclo celular, especialmente a passagem da fase G1-S. Importantes fatores envolvidos compõem a cascata da proteína Rb (p16, ciclina D1, CDK4 e pRb) e da proteína p53 (p53 e p21). Objetivo: verificar a frequência da expressão de p16, ciclina D1,CDK4, pRb, p53 e p21 em melanomas cutâneos de cabeça, pescoço e tronco e sua relação com prognóstico. Métodos: Estudo retrospectivo envolvendo 46 pacientes (sendo 67,3% homens, idade média 57,7 ± 15,8 anos) com melanoma cutâneo de cabeça, pescoço e tronco que foram tratados pela mesma equipe com seguimento mínimo de dois anos. Foram estudados fatores clínicos (topografia do tumor primário, tempo de seguimento, ocorrência de metástases e óbito relacionado), histopatológicos (tipo histológico, índice de Clark, índice de Breslow) e análise imuno-histoquímica pela técnica de micro-array para as proteínas reguladoras do ciclo celular p16, ciclina D1, CDK4, pRb, p53 e p21. Resultados: Houve proporção igualitária entre as topografias (23 casos em tronco, 23 em cabeça e pescoço). Treze pacientes com Clark I (29,5%), cinco com II (11,3%), 16 com III (36,5%), 10 com IV (22,7%) e nenhum com Clark V. A média das medidas de Breslow foi 0,96 (DP=1,01). O seguimento médio foi de 77 meses (DP=47). Oito dos 46 pacientes (17,3%) tiveram evolução desfavorável, com seis óbitos relacionados. A idade foi mais elevada no grupo com evolução desfavorável (p=0,04). Houve expressão de p16 em 80%, ciclina D1 em 58,9%, CDK4 em 43,5%, pRb em 58,5%, p53 em 53,6% e p21 em 52,3% dos melanomas. Em análise univariada, a expressão do p21 foi relacionada com evolução desfavorável (p=0,04), o que não foi observado com a expressão dos outros marcadores (p>0,05). Conclusão: A expressão da proteína p21 nos melanomas cutâneos de cabeça, pescoço e tronco foi relacionada com evolução desfavorável, o que não ocorreu com outros fatores envolvidos na regulação do ciclo celular / Melanoma is the most lethal skin cancer. The outcome of melanoma is not predictable in most cases. Although the treatment for the primary tumor is well tolerated, there are no effective therapeutic options in disseminated disease. Efforts are being made in the search for tumoral markers that may predict outcome, increase the comprehension of melanoma pathogenesis, and may also help the search for molecular targets. In this issue, genetic studies concerning the regulation of cell cycle, including the G1-S checkpoint, are important. The retinoblastoma protein (pRb) pathway (p16, cyclin D1, CDK4 and pRb) and the p53 pathway (p53 and p21) are part of this regulation. Objectives: to verify the expression of p16, cyclin D1, CDK4, pRb, p53 and p21 in head, neck and trunk melanomas, and its correlation with prognosis. Method: Retrospective study approved by institution ethics committee. Fourtysix head, neck and trunk melanoma patients (67.3% men, mean age 57.7±15.8) treated by a single surgeon with minimum 2-years follow-up were enrolled. Clinical factors (primary tumor location, follow-up period, metastasis or related deaths), pathologic (histological subtype, Clark and Breslow index) and microarray immunohystochemical analysis of the cell cycle proteins p16, cyclin D1, CDK4, pRb, p53 and p21. Results: Location of the primary tumor was equal for head/neck and trunk (50% each). Thirteen patients were classified as Clark I (29.5%), five as Clark II (11.3%), 16 as Clark III (36.5%), 10 as IV (22.7%), none as Clark V. Mean Breslow measure was 0.96±1.01. Mean follow-up was 77±47 months. Eight patients (17.3%) had bad outcome, with six related deaths. Patients with worse outcome had a higher mean age at diagnosis (p=0,04). Expression of p16 was positive in 80%. Cyclin D1 was positive in 58.9%. CDK4 was positive in 43.5%. pRb was positive in 58.5%. p53 was positive in 53.6%. p21 was positive in 52.3%. Univariated analysis showed that p21 expression was related to worse outcome (p=0,04), while the other markers were not (p>0,05). Conclusion: p21 expression in head, neck and trunk melanomas was related to worse outcome. Expression of the other cell cycle regulators proteins was not
|
100 |
Análise de proteínas cuja expressão é controlada por miRNA e relacionada à progressão do adenocarcinoma de próstata por imuno-histoquimica em tissue microarray / Analysis of proteins whose expression is controlled by miRNA and related to the progression of prostate adenocarcinoma by immunohistochemistry on tissue microarrayTimoszczuk, Luciana Maria Sevo 24 October 2012 (has links)
Introdução: O Câncer de Próstata (CaP) é o tumor mais comum do homem e a segunda causa de óbito por câncer no Brasil. MicroRNA (miRNA) é uma classe de pequenos RNA regulatórios não codificantes de proteínas que tem papel fundamental no controle da expressão dos genes. São responsáveis pelo controle de processos fundamentais na célula e estão envolvidos na tumorigênese em humanos. Previamente demonstramos alterações no perfil de expressão dos miRNA 100, let7c e 218 comparando carcinomas localizados e metastáticos. A caracterização de perfis de expressão de suas proteínas alvo no CaP é crucial para a compreensão dos processos envolvidos na carcinogênese, dando-nos a oportunidade do descobrimento de novos marcadores diagnósticos, prognósticos e mais importante identificação de alvos para o desenvolvimento de terapias inovadoras. Objetivo: Analisar a expressão das proteínas controladas pelo miR-let7c (Ras, c-Myc e Bub1), miR-100 (Smarca5 e Retinoblastoma) e miR-218 (Laminina 5 3) e a atividade proliferativa (Ki-67) no câncer de próstata com a técnica de imuno-histoquímica utilizando microarranjos teciduais representativos de CaP localizado e suas metástases linfonodais e ósseas. Correlacionar os níveis de expressão dos miRNA com suas proteínas alvo. Analisar a expressão dos miRNA, proteínas e atividade proliferativa com os fatores prognósticos do câncer de próstata e com a evolução da doença. Material e Métodos: A imunoexpressão de Smarca5, Retinoblastoma, Laminina, Ras, c- Myc, Bub1 e Ki-67 foi avaliada através de IH pela técnica de microarranjo tecidual caracterizando três estágios do CaP, sendo 112 casos de CaP localizado, 19 metástases linfonodais e 28 metástases ósseas. As imagens obtidas foram submetidas a um software de análise de imagem digital MacBiophotonics ImageJ do National Institutes of Health, EUA, onde a intensidade de luminescência foi quantificada densitometricamente. O perfil de expressão dos miR-let7c, 100 e 218 foi analisado utilizando o bloco de parafina de 61 pacientes dos 112 pacientes com carcinoma localizado, que foram submetidos a analise protéica por IH. O processamento dos miRNA envolveu três etapas: extração do miRNA com kit específico, geração do DNA complementar e amplificação do miRNA por PCR quantitativo em tempo real (qRT-PCR) cujo controle endógeno foi RNU-43 (Applied Biosystems). Os resultados foram analisados usando o método 2-CT. Como controle, utilizamos amostras de tecido com hiperplasia prostática benigna (HPB). Avaliamos a relação entre a expressão dos miRNA e suas proteínas alvo, com o escore de Gleason, estadiamento patológico e evolução da doença considerando recidiva bioquímica, níveis de PSA>0,4 ng/mL, em uma média de seguimento de 77,5 meses. A análise estatística foi realizada através do software SPSS 19.0, utilizamos o test T de Student, Mann-Whitney, Kruskal-Wallis e qui-quadrado. O valor de p foi considerado estatisticamente significante quando inferior na 0,05 em todos os cálculos. Resultados: Observamos uma diminuição de expressão de Ras (p=0,017) e Laminina (p<0,0001) conforme a progressão tumoral do CaP localizado a metástase linfonodal e óssea. Houve um aumento de expressão de Rb (p=0,0361) e aumento da atividade proliferativa avaliada pelo Ki- 67 (p<0,0001). Encontramos ainda uma tendência a relação entre a positividade de expressão de c-Myc com estadiamento patológico pT3 (p=0,070). Todos os miRNA se mostraram superexpressos no CaP localizado. Laminina apresentou uma média de intensidade de expressão maior quanto maior a expressão de miR-218 (p=0,038). Porém os demais miRNA não apresentaram relação de expressão com suas proteínas alvo. Também não houve relação entre a expressão de miRNA e expressão das proteínas por IH com a recidiva bioquímica. Conclusões: Apesar de confirmarmos os nossos achados de superexpressão dos miRNA 100, let7c e 218 no CaP localizado, não houve correlação entre esses e a imunoexpressão de suas proteínas alvo. Demonstramos que houve alteração de imunoexpressão de Ras, Laminina 5 3, Retinoblastoma e Ki-67 de acordo com a progressão tumoral no CaP. E uma maior expressão de c-Myc por IH mostrou uma significância tendência a relacionar-se com tumores não confinados estadiados pT3 / Introduction: Prostate cancer (PCa) is the most common tumor in men and the second leading cause of cancer death in men in Brazil. MicroRNA (miRNA) is a class of small non-coding RNA that plays a key role in the control of gene expression. They are responsible for the control of key processes in the cell and are involved in tumorigenesis in humans. Previously, we demonstrated alterations in the expression profile of miRNA 100, 218 and let7c comparing localized and metastatic carcinomas. The characterization of expression profiles of their target proteins in PCa is crucial to understanding the processes involved in carcinogenesis, giving us the opportunity to discover new diagnostic or prognostic markers, and most importantly to find new targets for the development of innovative therapies. Objective: To analyze the expression of proteins controlled by miR-let7c (Ras, c- Myc and Bub1), miR-100 (Smarca5 and Retinoblastoma) and miR- 218 (Laminin 5 3) and proliferative activity (Ki-67) in prostate cancer with immunohistochemistry using tissue microarrays representing localized PCa, lymph node and bone metastases. To correlate the expression levels of miRNAs with their target proteins. To analyze the expression of miRNAs, proteins and proliferative activity with prognostic factors of prostate cancer and disease progression. Methods: The immunoexpression of Smarca5, Retinoblastoma, Laminin, Ras, c-Myc, Bub1 and Ki-67 was evaluated by IHC by tissue microarray technique featuring three stages of PCa, with 112 cases of localized PCa, 19 lymph node metastases and 28 bone metastases. The images obtained from IHC were submitted to analysis using the digital image software MacBiophotonics ImageJ from the National Institutes of Health, USA, where the intensity of luminescence was quantified densitometrically. We studied the expression profile of the miRNAs in the paraffin blocks of 61 patients out of the 112 patients with localized carcinoma, who underwent protein analysis by IHC. The processing of miRNA involved three steps: extraction of miRNA, generation of complementary DNA and amplification of the miRNA by quantitative real time PCR (qRT-PCR). To analyze the data we used a control endogenous RNU-43. The results were analyzed using the 2-CT formula. As control, we used the tissue from five patients with benign prostate hyperplasia (BPH) submitted to surgery. The relationship between the expression of miRNAs and their target proteins were analyzed as well as their expression with Gleason score, pathological stage and disease progression considered as PSA>0.4 ng/mL in a mean follow-up of 77.5 months. The statistical analysis was performed using SPSS 19.0 software, we used the Student t test, Mann-Whitney test, Kruskal- Wallis and chi-square. The value was considered statistically significant when p0.05. Results: There was a decrease in the expression of Ras (p=0.017) and Laminin (p<0.0001) according to PCa progression from localized to lymph node and bone metastases. There was an increase in the expression of Retinoblastoma (p=0.0361) and an increase in proliferative activity assessed by Ki-67 (p<0.0001). We also found a relationship between the positivity of c-Myc expression with pT3 staged tumors (p=0.070). All miRNAs showed overexpression in PCa samples. Laminin showed a higher expression together with higher expression of miR-218 (p=0.038). The other miRNAs did not show a relationship with protein expression by IHC. There was no correlation between the expression of miRNAs and protein expression by IHC with biochemical recurrence. Conclusions: Although our findings confirm the overexpression of miR-100, 218 and let7c in localized PCa, there was no correlation between their expression and the protein of their target using immunohistochemistry. We demonstrated that there was a change in immunostatining of Ras, Laminin 5 3, Retinoblastoma and Ki- 67 according to tumor progression. The increased expression of c- Myc per IHC showed a significant tendency to relate to tumor unconfined staged pT3
|
Page generated in 0.0476 seconds